GSK is facing a patent lawsuit from Sandoz and ruling will be given out in 30-45 days. If they lose patent, how does this affect ARMN? Do managed care plans restrict AMRN product until you fail on a cheaper generic Lovaza? I know a lot depends on the difference in the FDA label for AMRN product. Does anyone have insights to the difference in their label vs Lovaza? Does this make GSK a more aggressive bidder for AMRN because they have other CV products in the pipeline and want to remain a player in this market?